Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine add-on therapy in high-risk primary membranous nephropathy
IRCT20261005071301N1Phase 3Not yet recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydroxychloroquine in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Complete proteinuria remission. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on IRCT20261005071301N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20261005071301N1.